Cytek Biosciences (NASDAQ: CTKB) furnishes preliminary 2025 revenue update

Rhea-AI Filing Summary

Cytek Biosciences, Inc. reported that it has issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company furnished this press release as Exhibit 99.1 to a current report, rather than treating it as formally filed financial information. The filing clarifies that the press release and related data are not incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001831915 0001831915 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 12, 2026

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40632		47-2547526
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
47215 Lakeview Boulevard Fremont, California				94538
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CTKB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Cytek Biosciences, Inc. issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The press release is being furnished as Exhibit 99.1.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description of Exhibit
99.1		Press release dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Cytek Biosciences, Inc.
Date: January 13, 2026				By:		/s/ Wenbin Jiang
						Wenbin Jiang, Ph.D. President and Chief Executive Officer

FAQ

What did Cytek Biosciences (CTKB) disclose in this 8-K?

Cytek Biosciences, Inc. disclosed that it issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025, and furnished that release as Exhibit 99.1.

Does the Cytek Biosciences 8-K include detailed revenue figures?

The 8-K states that Cytek Biosciences announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025, but the specific figures are contained in the press release furnished as Exhibit 99.1, not in the body of the report.

How is the preliminary revenue information for Cytek Biosciences treated legally?

The company states that the information furnished under Item 2.02 and the attached exhibit shall not be deemed “filed” under Section 18 of the Exchange Act or incorporated by reference into other Securities Act or Exchange Act filings, except where specifically referenced.

Which exhibit in the Cytek Biosciences 8-K contains the revenue press release?

Exhibit 99.1 to the report is identified as the press release dated January 12, 2026 that announces Cytek Biosciences’ preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025.

Who signed the Cytek Biosciences 8-K related to preliminary 2025 revenue?

The report was signed on behalf of Cytek Biosciences, Inc. by Wenbin Jiang, Ph.D., who is the President and Chief Executive Officer.

What period does Cytek Biosciences’ preliminary revenue announcement cover?

The preliminary unaudited revenue announcement covers both the fourth quarter and the full year ended December 31, 2025.